Acceleron Pharma Inc (NASDAQ:XLRN) SVP Christopher Rovaldi sold 11,000 shares of the business’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $45.00, for a total value of $495,000.00. Following the completion of the transaction, the senior vice president now owns 35,701 shares in the company, valued at approximately $1,606,545. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Christopher Rovaldi also recently made the following trade(s):
- On Wednesday, January 3rd, Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock. The shares were sold at an average price of $42.42, for a total value of $96,123.72.
Shares of Acceleron Pharma Inc (NASDAQ XLRN) opened at $44.99 on Thursday. Acceleron Pharma Inc has a 52 week low of $23.07 and a 52 week high of $46.93. The stock has a market capitalization of $2,036.48, a P/E ratio of -17.37 and a beta of 1.59.
Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. During the same quarter in the prior year, the company earned ($0.55) EPS. Acceleron Pharma’s revenue was up .0% on a year-over-year basis. analysts predict that Acceleron Pharma Inc will post -2.65 earnings per share for the current year.
Several equities analysts recently issued reports on the company. HC Wainwright boosted their price target on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, November 7th. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, November 14th. Royal Bank of Canada reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Finally, Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. Acceleron Pharma has an average rating of “Buy” and an average target price of $44.56.
A number of hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in Acceleron Pharma by 9.0% in the 2nd quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after acquiring an additional 330,635 shares during the last quarter. Vanguard Group Inc. raised its holdings in Acceleron Pharma by 6.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after acquiring an additional 116,705 shares during the last quarter. Perceptive Advisors LLC raised its holdings in Acceleron Pharma by 127.2% in the 3rd quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after acquiring an additional 905,000 shares during the last quarter. State Street Corp raised its holdings in Acceleron Pharma by 9.4% in the 2nd quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock valued at $34,386,000 after acquiring an additional 97,199 shares during the last quarter. Finally, Sectoral Asset Management Inc raised its holdings in Acceleron Pharma by 378.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after acquiring an additional 478,099 shares during the last quarter. 85.70% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Acceleron Pharma Inc (XLRN) SVP Christopher Rovaldi Sells 11,000 Shares of Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/18/acceleron-pharma-inc-xlrn-svp-christopher-rovaldi-sells-11000-shares-of-stock.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.